Liver Transplantation
Treatment for Liver cancer due to NASH
Effectiveness
95%
Safety Score
25%
Clinical Trials
5,000
Participants
200K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Time to Effect
immediate
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
8(Treat 8 patients to see 1 additional serious adverse event)
Confidence Score
92%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$15,000
Monitoring:$10,000
Side Effect Mgmt:$15,000
Total Annual:$40,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$100,000/QALY
QALYs Gained
7
Outcome-Based Costs
Cost per Responder
$40,000
Cost per Remission
$53,333
Comparison vs Hepatic Resection
Cost Difference
+$500,000/year
More expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
No dominance
Liver Transplantation Outcomes
for Liver cancer due to NASH
Efficacy Outcomes
Overall Effectiveness
+95%
Response Rate
+100%
Remission Rate
+75%
Common Side Effects
Surgical complications (bleeding, infection)
+15%
Acute rejection
+18%
Chronic kidney disease (due to immunosuppressants)
+20%
Infections (opportunistic)
+40%
Recurrence of HCC
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov